Autopsy report · NCT02601274

Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor

“the change of clinical development plan”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months after it had already started.
• Ran for about 3 years 8 months before it stopped.
• 33 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Hutchison Medipharma Limited

Sponsor type

Industry

Conditions

Cancer

Interventions

Theliatinib

Participants

33

Sites

2

Countries

China

Trials that died the same way

• Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
  “Change in the clinical development plan” (99% match in meaning)
• Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee
  “Amended clinical development plan.” (87% match in meaning)
• A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia
  “Development plan change” (76% match in meaning)
• Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS
  “Change in development plan” (75% match in meaning)
• Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
  “Change in clinical plan and drug supply” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.